TABLE 1.
Baseline characteristics of included studies.
| Author | Study Design | Registration number | Start of data | Country | Sample Size | Age, years (Mean/Median) | Sex, % (male) | Histological type, n | CAR T | Mode of Transduction | Co-stimulatory Domain | Dose | Original T Cell Sources | Lymphodepletion | Does |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ayuk (2020) | Clinical trial, CA | — | — | Germany | 18 | — | — | DLBCL 18 | axi-cel | retroviral vector | CD28 | — | autologous | — | — |
| Jacobson et al. (2019) | ZUMA-6, CA | NCT02926833 | Sep-16 | United States of America | 12 | 55 (30–66) | — | DLBCL 12 | axi-cel | retroviral vector | CD28 | 2 × 10⁶ | autologous | — | — |
| (Cohort 1) Jacobson et al. (2020) | ZUMA-9, CA | NCT03153462 | — | United States of America | 25 | 56 (28–76) | 60 | DLBCL 20 | axi-cel | retroviral vector | CD28 | 2 × 10⁶ | autologous | fludarabine + cyclophosphamide | fludarabine: 30 mg/m2/day for 3 days; cyclophosphamide: 500 mg/m2/day for 3 days |
| Locke et al. (2019) | ZUMA-1 | NCT02348216 | Jan-15 | USA/Israel | 111 | 58 (23–76) | 67 | PMBCL 8/TFL 16 | axi-cel | retroviral vector | CD28 | 2 × 10⁶ | autologous | fludarabine + cyclophosphamide | fludarabine: 30 mg/m2 body-surface area per day, days −5, −4, and −3; cyclophosphamide: 500 mg/m2 body-surface area per day, days −5, −4, and −3 |
| Huang et al. (2020) | Clinical trial | NCT01865617 | May-13 | China | 11 | 49 (29–69) | 72.7 | DLBCL 9 | lab | lentiviral vector | 4-1BB | 1.8–3×106 | autologous | fludarabine + cyclophosphamide | fludarabine: 25 mg/m2/d (d1–3),cyclophosphamide: 900 mg/m2/d (d3–4) |
| Kochenderfer et al. (2017) | Clinical trial | NCT00924326 | Feb-09 | France | 19 | — | — | DLBCL-NOS 13/TFL 4/PMBCL 2 | lab | retroviral vector | CD28 | 1 × 10⁶, 2 × 10⁶, 6 × 10⁶ | autologous | fludarabine + cyclophosphamide | Fludarabine:30 mg/m2, Days -5 to -3; cyclophosphamide: 300 or 500 mg/m2, Days -5 to -3 |
| Yan et al. (2019) | Clinical trial | NCT03355859 | Jan-18 | China | 10 | 47 (32–59) | 80 | GCBC 2/Non-GCBC 7/MZBCL 1 | lab | lentiviral vector | 4-1BB | 2.5 × 107, 5.0 × 107, 1.0 × 108 | autologous | fludarabine + cyclophosphamide | fludarabine: 25 mg/m2/day; cyclophosphamide: 250 mg/m2/day on Day -4 to Day -2 |
| Zhou et al. (2020) | Clinical trial | ChiCTR-OOC-16007,779 | May-16 | China | 21 | — | 62 | DLBCL 12/High-grade BCL 1/PMLBCL 1 | lab | lentiviral vector | CD28, CD27 (4th generation) | median dose, 8.9×105 (0.3×105–48.0×105) | autologous | fludarabine + cyclophosphamide | fludarabine: 25 mg/m2 for 3 days; cyclophosphamide: 900 mg/m2 for 1 day |
| Abramson et al. (2020) | TRANSCEND NHL 001 | NCT 02631044 | Jan-16 | United States of America | 269 | 63 (18–86) | 65 | DLBCL-NOS 137/TFL 60/PMBCL 15/DHL THL 36/Grade 3B GFL 3 | liso-cel | lentiviral vector | 4-1BB | 50 × 10⁶, 100 × 10⁶, 150 × 10⁶ | autologous | fludarabine + cyclophosphamide | fludarabine: 30 mg/m2 daily for 3 days; cyclophosphamide: 300 mg/m2 daily for 3 days |
| Godwin et al. (202) | OUTREACH, CA | NCT03744676 | Nov-18 | United States of America | 46 | 63 (34–83) | — | DLBCL-NOS 29 | liso-cel | lentiviral vector | 4-1BB | — | autologous | — | — |
| Ying et al. (2021) | RELIANCE | NCT04089215 | Jun-19 | China | 59 | 56 (18–75) | 55.9 | DLBCL-NOS 41/TFL 9/PMBCL 4/Grade 3B FL 2/DHL THL 3 | relma-cel | lentiviral vector | 4-1BB | 100 × 10⁶, 150 × 10⁶ | autologous | fludarabine + cyclophosphamide | fludarabine: 25 mg/m2 i.v. daily, for 3 days; cyclophosphamide: 250 mg/m2 i.v. daily, for 3 days |
| Chavez et al. (2020) | clinical trial, CA | — | United States of America | 10 | arm 1: 59 (32–67); arm 2: 64 (58–76) | — | ABC 3, GCB 3 | tisa-cel | lentiviral vector | 4-1BB | 0.6–6.0×108 | autologous | fludarabine + cyclophosphamide/bendamustine | 1. fludarabine (25 mg/m2) and cyclophosphamide (250 mg/m2) daily for 3 days 2. bendamustine (90 mg/m2) daily for 2 days | |
| Schuster et al. (2019) | Juliet | NCT 02445248 | Jul-15 | USA/Australia/Canada/France/Germany/Italy/Japan/Nertherlands/Norway | 111 | 56 (22–76) | — | DLBCL-NOS 88/TFL 21/DHL 19/THL 70 | tisa-cel | lentiviral vector | 4-1BB | median dose, 3.0×108 (0.1×108–6.0×108 | autologous | fludarabine + cyclophosphamide/bendamustine | 1. fludarabine (25 mg/m2) and cyclophosphamide (250 mg/m2) daily for 3 days 2. bendamustine (90 mg/m2) daily for 2 days |
| Nastoupil et al. (2020) | RWS | — | Sep-18 | United States of America | 298 | 60 (21–83) | 64 | DLBCL 203/PMBCL 19/TFL 76 | axi-cel | retroviral vector | CD28 | — | autologous | fludarabine + cyclophosphamide | fludarabine: 30 mg/m2 body-surface area per day, days −5, −4, and −3; cyclophosphamide: 500 mg/m2 body-surface area per day, days −5, −4, and −3 |
| Sesques et al. (2020) | RWS | — | Jan-18 | France | 61 | 59 (27–75) | 66 | DLBCL 38/PMBCL 4/TFL 18/TMZL 1 | tisa-cel, axi-cel | retroviral vector, lentiviral vector | CD28, 4-1BB | — | autologous | fludarabine + cyclophosphamide/bendamustine | 1. (for axi-cel)fludarabine: 30 mg/m2 day 1 to day 3 and cyclophosphamide: 500 mg/m2, day -5 to day -3; (for tisa-cel)fludarabine: 30 mg/m2 day 1 to day 3 and cyclophosphamide: 250 mg/m2, day -5 to day -3 2.bendamustine: 90 mg/m2 day -5 and day -4 |
| Jaglowski et al. (2019) | RWS, CA | — | — | United States of America | 70 | 65.11 (18.5–88.9) | 61.4 | high-grade BCL 22/DLBCL 21/GCBC 13/ABC 10 | tisa-cel | lentiviral vector | 4-1BB | — | autologous | — | — |
| Iacoboni et al. (2021) | RWS | — | Dec-18 | Spain | 75 | 60 (52–67) | 59 | DLBCL-NOS 44/DH TH 11/TFL 17 | tisa-cel | lentiviral vector | 4-1BB | 3.5 × 108 | autologous | fludarabine + cyclophosphamide | fludarabine: 25 mg/m2/day, for 3 days; cyclophosphamide: 250 mg/m2/day, for 3 days |
| Faramand et al. (2019) | Prospective,CA | — | — | United States of America | 20 | 64 (43–73) | — | r/r DLBCL 20 | axi-cel | retroviral vector | CD28 | — | autologous | — | — |
| Dean et al. (2019) | Retrospective, CA | — | Jun-15 | United States of America | 48 | 63 (28–76) | 64.6 | — | axi-cel | retroviral vector | CD28 | — | autologous | — | — |
| Grana et al. (2021) | Retrospective | — | Jan-18 | United States of America | 37 | 59 (23–75) | 59.5 | DLBCL 22/PMBCL 4/High grade BCL 2/TFL 9 | axi-cel | retroviral vector | CD28 | — | autologous | — | — |
| Melody et al. (2019) | Retrospective, CA | — | Jun-18 | United States of America | 50 | 53 (26–67) | 74 | DLBCL 27/PMBCL 5/TFL 8/High grade BCL 7 | axi-cel | retroviral vector | CD28 | — | autologous | — | — |
| Mian et al. (2020) | Retrospective, CA | — | May-18 | 27 | 63 (48–68) | 67 | r/r BCL 27 | axi-cel | retroviral vector | CD28 | — | autologous | — | — | |
| Panaite et al. (2020) | Retrospective, CA | — | Feb-18 | United States of America | 53 | 63 (25–79) | 68 | DLBCL 41/PMBCL 1/TFL 11 | axi-cel | retroviral vector | CD28 | — | autologous | — | — |
| Pennisi et al. (2020) | Retrospective | — | Feb-18 | United States of America | 49 | 64 (20–85) | 69 | DLBCL 49 | axi-cel, tisa-cel | retroviral vector, lentiviral vector | CD28, 4-1BB | — | autologous | — | — |
| Strati et al. (2019) | Retrospective, CA | — | Jan-18 | United States of America | 95 | 60 (18–85) | 71 | DLBCL 71/TFL 17/PMLBCL 6 | axi-cel | retroviral vector | CD28 | — | autologous | — | — |
| Iacoboni et al. (2020) | Retrospective, CA | — | Dec-18 | Spain | 45 | 53 (23–72) | 64 | r/r DLBCL 45 | tisa-cel | lentiviral vector | 4-1BB | — | autologous | — | — |
| Lee et al. (2020) | Retrospective, CA | — | Jan-19 | United States of America | 37 | 60, SD 18 | 65 | DLBCL 37 | tisa-cel | lentiviral vector | 4-1BB | — | autologous | — | — |
Abbreviation; DLBCL-NOS, DLBCL, not otherwise specified; PMBCL, primary mediastinal B-cell lymphoma; FL, Follicular lymphoma; DHL/THL, double-/triple-hit lymphoma; liso-cel, Lisocabtagene maraleucel; tisa-cel, Tisagenlecleucel; relma-cel, Relmacabtagene autoleucel; axi-cel, Axicabtagene ciloleucel